Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Morphometricity as a measure of the neuroanatomical signature of a trait.

Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. doi: 10.1073/pnas.1604378113. Epub 2016 Sep 9.

2.

Synthesis of (±)-Bisavenanthramide B-6 by an Anionic Anhydride Mannich Reaction.

Di Maso MJ, Nepomuceno GM, St Peter MA, Gitre HH, Martin KS, Shaw JT.

Org Lett. 2016 Apr 15;18(8):1740-3. doi: 10.1021/acs.orglett.6b00413. Epub 2016 Mar 29.

PMID:
27023166
3.

The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume.

Lupton MK, Strike L, Hansell NK, Wen W, Mather KA, Armstrong NJ, Thalamuthu A, McMahon KL, de Zubicaray GI, Assareh AA, Simmons A, Proitsi P, Powell JF, Montgomery GW, Hibar DP, Westman E, Tsolaki M, Kloszewska I, Soininen H, Mecocci P, Velas B, Lovestone S; Alzheimer's Disease Neuroimaging Initiative, Brodaty H, Ames D, Trollor JN, Martin NG, Thompson PM, Sachdev PS, Wright MJ.

Neurobiol Aging. 2016 Apr;40:68-77. doi: 10.1016/j.neurobiolaging.2015.12.023. Epub 2016 Jan 11.

PMID:
26973105
4.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

5.

Effective Teaching-Learning Strategies for the Omaha System.

Radhakrishnan K, Martin KS, Johnson KE, Garcia AA.

Home Healthc Now. 2016 Feb;34(2):86-92. doi: 10.1097/NHH.0000000000000335.

PMID:
26835807
6.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

7.

Highly adaptive tests for group differences in brain functional connectivity.

Kim J, Pan W; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2015 Oct 22;9:625-39. doi: 10.1016/j.nicl.2015.10.004. eCollection 2015.

8.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3. Epub 2015 Nov 10.

PMID:
26555082
9.

MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.

Hua X, Ching CR, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:26-37. doi: 10.1016/j.neurobiolaging.2015.09.018. Epub 2015 Oct 19.

10.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:208.e1-9. doi: 10.1016/j.neurobiolaging.2015.09.009. Epub 2015 Sep 25.

PMID:
26545630
11.

Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment.

David ND, Lin F, Porsteinsson AP; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2016 Jan;24(1):70-80. doi: 10.1016/j.jagp.2015.06.001. Epub 2015 Jun 27.

PMID:
26525995
12.

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW, Blennow K; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2016 Jan;73(1):60-7. doi: 10.1001/jamaneurol.2015.3037.

PMID:
26524180
13.

Feasibility of Using the Omaha System for Community-level Observations.

Kerr MJ, Flaten C, Honey ML, Gargantua-Aguila Sdel R, Nahcivan NO, Martin KS, Monsen KA.

Public Health Nurs. 2016 May;33(3):256-63. doi: 10.1111/phn.12231. Epub 2015 Oct 1.

PMID:
26429415
14.

Suspected non-AD pathology in mild cognitive impairment.

Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, Yushkevich PA, Wolk DA; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2015 Dec;36(12):3152-62. doi: 10.1016/j.neurobiolaging.2015.08.029. Epub 2015 Sep 7.

PMID:
26422359
15.

Study of amyloid-β peptide functional brain networks in AD, MCI and HC.

Jiang J, Duan H, Huang Z, Yu Z; Alzheimer's Disease Neuroimaging Initiative.

Biomed Mater Eng. 2015;26 Suppl 1:S2197-205. doi: 10.3233/BME-151525.

PMID:
26405999
16.

Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease.

Wang C, Tan L, Wang HF, Yu WJ, Liu Y, Jiang T, Tan MS, Hao XK, Zhang DQ, Yu JT; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):491-5. doi: 10.3233/JAD-150110.

PMID:
26402410
17.

Identification of Conversion from Normal Elderly Cognition to Alzheimer's Disease using Multimodal Support Vector Machine.

Zhan Y, Chen K, Wu X, Zhang D, Zhang J, Yao L, Guo X; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(4):1057-67. doi: 10.3233/JAD-142820.

PMID:
26401783
18.

Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Malpas CB, Saling MM, Velakoulis D, Desmond P, O'Brien TJ; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(4):965-75. doi: 10.3233/JAD-142643.

PMID:
26401775
19.

Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study.

Klöppel S, Peter J, Ludl A, Pilatus A, Maier S, Mader I, Heimbach B, Frings L, Egger K, Dukart J, Schroeter ML, Perneczky R, Häussermann P, Vach W, Urbach H, Teipel S, Hüll M, Abdulkadir A; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(4):939-54. doi: 10.3233/JAD-150334.

20.

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.

Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(3):729-40. doi: 10.3233/JAD-150066.

PMID:
26401707
Items per page

Supplemental Content

Loading ...
Write to the Help Desk